Conclusions This open-label, single-center pilot study suggests that GLP-1-RAs are an effective and safe treatment option for achieving significant weight loss with a favorable effect on headache, leading to reduced acetazolamide dosage in pwIIH
This article will examine the clinical considerations of using these two medications together, how they might influence each others effectiveness, and what you should discuss with a healthcare provider

Plaintiffs in the litigation report experiencing these specific digestive system complications: Gastroparesis (stomach paralysis): The most common injury alleged in lawsuits, this condition involves partial or complete paralysis of stomach muscles that prevents proper digestion and can persist even after discontinuing medication Ileus (intestinal blockage): Added to FDA warning labels in September 2023 after post-marketing reports, this condition stops intestinal movement and can lead to life-threatening complications including infection and tissue death Intestinal obstruction and pseudo-obstruction: Physical or functional blockages requiring emergency hospitalization and often surgical intervention to prevent bowel perforation Chronic severe symptoms: Persistent vomiting, uncontrollable nausea, dangerous dehydration requiring IV fluids, and electrolyte imbalances necessitating repeated emergency department visits The FDAs decision to update warning labels demonstrates growing concern about these complications

The nausea is both dose-dependent and time-dependent, meaning higher doses produce more nausea, and symptoms are most prominent during treatment initiation before the body adapts to the medications effects
Also known as gastroparesis, this is a chronic, often irreversible disorder that occurs when the stomach takes too long to empty food and can cause life-threatening health complications
By weeks four to eight, most patients report better control over their appetite and find it easier to manage portion sizes, contributing to healthier eating habits